ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit

Core Points - Rosen Law Firm is reminding purchasers of aTyr Pharma, Inc. common stock about the lead plaintiff deadline for a class action lawsuit, which is December 8, 2025 [1][3] - Investors who purchased aTyr Pharma stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit claims that aTyr Pharma provided misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]